Radiopharm Theranostics Limited has recently reported compelling interim results from its Phase 2b imaging study of RAD101, aimed at diagnosing suspected recurrent brain metastases following radiotherapy. The announcement was made on November 16, 2026, during the Society for Neuro-Oncology Annual Meeting. This development is significant as it may improve diagnostic capabilities in a field where accurate imaging is crucial for effective treatment decisions.
Radiopharm Theranostics, an emerging growth company in the pharmaceutical preparations sector (SIC 2834), is focused on developing innovative oncology radiopharmaceuticals. The company is listed on both the Nasdaq and the Australian Securities Exchange, trading under the tickers RADX and RAD, respectively. Their recent filings indicate a strong commitment to advancing their clinical programs, which include multiple trials for various types of cancer.
The filing, accession number 0001213900-26-120153, details the positive outcomes from the RAD101 imaging study. The study demonstrated a remarkable 93.5% patient-level agreement between RAD101 PET and contrast-enhanced MRI, with a preliminary sensitivity of 85.7% against the reference standard. Furthermore, no serious treatment-emergent adverse events were reported among the 32 participants dosed, indicating a favorable safety profile for RAD101.
This interim analysis is particularly relevant for clinicians who face challenges in distinguishing between recurrent disease and treatment-related effects. According to Riccardo Canevari, CEO of Radiopharm, the results underscore the urgent need for more accurate diagnostic tools in neuro-oncology. The company is also aligning with the U.S. FDA for a pivotal Phase 3 imaging trial, which could further solidify RAD101's position in the market.
The implications of these findings extend beyond Radiopharm Theranostics. The results may influence other companies within the pharmaceutical preparations industry, particularly those developing similar diagnostic tools for brain metastases. As the incidence of intracranial metastatic disease continues to rise, advancements in imaging technologies like RAD101 could shift competitive dynamics significantly.
Looking ahead, Radiopharm plans to report additional diagnostic accuracy data and complete follow-up analyses in Q1 2027. This ongoing commitment to research and development is critical as the company seeks to establish itself as a leader in the oncology diagnostics space.
Read Next
Mettler Toledo officer acquires 64 shares in performance reward
Lauber Scott J Executes Major Stock Transactions at WEC Energy
Deming acquires 12,000 shares in Phio Pharmaceuticals Corp.
Deprati Christian Ferdinando Emilio Acquires 3,000 Shares
Rebecca Underwood forfeits 9,523 shares at Clean Harbors
SS Innovations CEO Sudhir Srivastava Sells 20,000 Shares








